AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01767389 — intervention group
Intervention type: OTHER
Intervention: DPP-4 inhibitor users
Description: DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
Study NCT01767389 — intervention group
Intervention type: OTHER
Intervention: Other ADA users
Description: Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
Study NCT01818024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single IV dose of GSK2862277
Description: GSK2862277 solution available in a 40 mg vial for IV administration.
Study NCT03188029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: adrenocortical function
Description: Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.~Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate.
Study NCT01271738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remove tumor only
Description: No additional margins (tissue) removed at the initial surgery
Study NCT01271738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of tumor and tissue
Description: 5 additional margins (tissue) removed at the time of surgery
Study NCT04333173 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular procedure
Description: Endovascular therapies for erectile dysfunction
Study NCT01818024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo single dose IV infusion
Description: Matching placebo solution available for IV administration.
Study NCT00696150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: determination of method with highest efficacy (ultrasound or nerve stimulator)
Description: Use of ultrasound to guide the insertion of anterior psoas compartment block
Study NCT00696150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve stimulator
Description: The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
Study NCT01818024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single IH dose of GSK2862277
Description: GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
Study NCT01818024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo single dose IH
Description: Matching placebo nebulised solution available for IH administration.
Study NCT00696150 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: loss of resistance
Description: Use of ultrasound to guide the insertion of anterior psoas compartment block
Study NCT01818024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repeat IV dose of GSK2862277
Description: GSK2862277 solution available in a 40 mg vial for IV administration.
Study NCT01818024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo repeat dose IV infusion
Description: Matching placebo solution available for IV administration.
Study NCT01818024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repeat IH dose selected of GSK2862277 from Part 2
Description: GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
Study NCT01818024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo repeat dose IH
Description: Matching placebo nebulised solution available for IH administration.
Study NCT03407677 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ROTO track®
Description: An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
Study NCT01885117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIVf
Description: Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
Study NCT04380181 — intervention group
Intervention type: DRUG
Intervention: dobu
Description: Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass
Study NCT00865644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% Cream
Description: Applied topically to three tumors 5 times per week for a full 6 weeks
Study NCT03262701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide Gel, 13 weeks
Description: 13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
Study NCT03262701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide Gel, 26 weeks
Description: 26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
Study NCT03262701 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scaling and Root planing group
Description: Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without custom tray application of 1.7% peroxide gel
Study NCT03903796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10234
Description: Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
Study NCT00249561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery by Choice
Description: The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive.
Study NCT00249561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Intensive Outpatient Program (IOP)
Description: The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg \& Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
Study NCT02220881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mold making silicone toe separator
Description: Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
Study NCT02220881 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
Study NCT01673061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: See associated Arm Description
Study NCT01673061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant
Description: See associated Arm Description
Study NCT00707577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based maintenance program
Description: The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
Study NCT02803216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard triple region
Description: ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
Study NCT02803216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard triple region
Description: ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
Study NCT02803216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-week Xiang-sha-liu-jun decoction
Description: 2-week Xiang-sha-liu-jun decoction, bid.
Study NCT02803216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-week Xiang-sha-liu-jun decoction
Description: 4-week Xiang-sha-liu-jun decoction, bid.
Study NCT01187225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen concentrate
Description: In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
Study NCT01187225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
Study NCT00101088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00101088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00101088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02278978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120
Description: BIBF1120 200 mg two times per day orally
Study NCT04403204 — intervention group
Intervention type: OTHER
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
Study NCT04403204 — intervention group
Intervention type: OTHER
Intervention: DCE-MRI
Description: Characterize the relationship between bone perfusion as quantified by ICG based DCE-FI and DCE-MRI in human patients to develop an accurate depth-sensitive fluorescence imaging model that will correct for the surface-weighted feature of fluorescence imaging
Study NCT02944071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter
Study NCT01926392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: water-soluble therapy
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
Study NCT01926392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: water-soluble therapy
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
Study NCT01926392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silver sulfadiazine
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
Study NCT01926392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver sulfadiazine
Description: The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
Study NCT04601909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FX-322
Description: active comparator
Study NCT03903796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-10234
Description: Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
Study NCT03903796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
Study NCT03903796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
Study NCT03857711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CABG
Description: Coronary artery bypass grafting
Study NCT04036565 — intervention group
Intervention type: BEHAVIORAL
Intervention: sunlight therapy
Description: Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
Study NCT03436589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indiana SNAP-Ed
Description: First four Indiana SNAP-Ed nutrition education lessons served as the intervention
Study NCT03306147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain education with follow up encounters
Description: Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
Study NCT03721328 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: vancomycin hydrochloride and tobramycin sulfate
Description: vancomycin hydrochloride and tobramycin sulfate via local irrigation
Study NCT03857711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG+ PVI
Description: CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins
Study NCT01733329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
Study NCT01733329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
Study NCT03484533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV self-test kit
Description: We will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits to HIV-positive pregnant women overcomes their male partners' reluctance to be tested in PMTCT clinics. Pregnant women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
Study NCT03857711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG+ PVI+amiodarone
Description: CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)
Study NCT03857711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG+amiodarone
Study NCT03826433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral iv
Description: 6\*10\^7 cells
Study NCT03484533 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
Study NCT01153490 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Intervention
Description: Substance-related
Study NCT01153490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Substance-related
Study NCT04538950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/CT
Description: Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
Study NCT03591458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
Study NCT03591458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
Study NCT04601909 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00371839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Audiological Evaluation
Description: Tests of hearing, cognition, and speech perception
Study NCT01899755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2800528, solution for injection
Description: Drug will be administered at 3 different dose levels by subcutaneous injection.
Study NCT01899755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% w/v Sodium Chloride), solution for injection
Description: Subcutaneous injection of. 0.8 mL solution will be administered
Study NCT01899755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab, solution for injection
Description: Subcutaneous injection of 0.8 mL solution will be administered (40mg)
Study NCT02724644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Injectable intervention
Study NCT02724644 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT03911037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF will be administered as prefilled syringes at a dosage of 5 μg/Kg subcutaneously every 12 hr for five consecutive days. Four such cycles will be administered at three monthly intervals.
Study NCT03911037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
Study NCT02488408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Study NCT00330096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hesperidin
Study NCT00330096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00780039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study NCT02488408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02488408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study NCT03183609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Flour in Protein Shake
Description: 15 Grams Gluten Flour BID
Study NCT03183609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice Flour in Protein Shake
Description: 15 Grams Rice Flour BID
Study NCT03957226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)
Description: The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
Study NCT02651272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan
Description: 10mg macitentan tablets
Study NCT02412085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~* body weight \< 80kg: 50 mg every 4 weeks~* body weight ≥ 80 kg: 100 mg every 4 weeks
Study NCT04538950 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: radioactive drug (tracer)
Description: A radioactive drug (tracer) is used in the PET scan.